Pure Global AI
NCT06082986Recruitment Completed

A Retrospective Observational Study of Ustekinumab Among Bio-naive Participants With Crohn's Disease in China

A Multicenter, Retrospective, Observational Study Using Real-world Data to Describe the Effectiveness, Treatment Pattern and Safety of Ustekinumab Among Bio-naive Patients With Crohn's Disease in China
Xian-Janssen Pharmaceutical Ltd.ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Crohn Disease
Drug/Device/Intervention
Ustekinumab
Study type
Observational
Intervention type
drug
Sponsor & location
Primary sponsor
Xian-Janssen Pharmaceutical Ltd.
Location
Hangzhou,Guangzhou,Guangzhou, China
Timeline & enrollment
Phase
N/A
Start date
Oct 09, 2023
End date
Dec 15, 2023
Enrollment
200 participants
Primary outcome

Percentage of Participants With Endoscopic Remission at Week 24

Summary

Bio-naive participants are defined as the participants who previously have not received any
 biologics for Crohn's Disease (CD).The purpose of this retrospective study is to describe the
 endoscopic remission at week 24 among bio-naive participants with CD treated with ustekinumab
 in China.

ICD-10 classifications
Crohn disease, unspecifiedOther Crohn diseaseCrohn disease of large intestineCrohn disease of small intestineCrohn disease [regional enteritis]
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06082986
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06082986 through Pure Global AI's free database. This phase not specified trial is sponsored by Xian-Janssen Pharmaceutical Ltd. and is currently Recruitment Completed. The study focuses on Crohn Disease. Target enrollment is 200 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.